Skip to content
Biotechnology

ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology

ZeptoMetrix 2 mins read

BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A H5N1 Quantitative Stock, a groundbreaking advancement in molecular diagnostic quality assurance. Leveraging phage-like particle encapsulated RNA technology, this product sets a new standard for accuracy and reliability in avian influenza (H5N1) detection, addressing critical gaps in laboratories' ability to validate end-to-end testing workflows.

As H5N1 outbreaks continue to rise globally, the need for robust quality control materials has never been greater. ZeptoMetrix's Influenza A H5N1 Quantitative Stock offers laboratories a comprehensive quality control material that requires RNA extraction, unlike traditional naked RNA products. This novel solution includes three encapsulated H5N1 gene segments within a phage-like particle, ensuring realistic validation of extraction, amplification, and detection steps.

"The ongoing H5N1 pandemic highlighted the urgent need for reliable diagnostic tools," said Dr. Karuna Sharma, PhD, Vice President & Chief Scientific Officer of Antylia Diagnostics division. "This launch represents a significant advancement in diagnostic quality control. By encapsulating RNA within a phage-like particle, we enable labs to have confidence in their results at every step. This is not just innovation; it is vital in the fight against H5N1 and other emerging RNA viruses."

NATtrol Influenza A H5N1 Quantitative Stock (Product Code: 0831198) is NATtrol inactivated to enhance stability and provided with precision quantification at 1,000,000 gene copies/mL of each gene segment, verified by digital PCR (dPCR). The ready-to-use 1 mL format integrates seamlessly with ZeptoMetrix's -STQ product line, streamlining workflow adoption.

More information on how to order and additional ZeptoMetrix products can be found at: www.zeptometrix.com

About ZeptoMetrix®

ZeptoMetrix, an Antylia Scientific company, is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services, have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.

Product Page: https://www.zeptometrix.com/us/en/nattrol-influenza-a-h5n1-quantitative-stock-1-x-10-ml-15355

Contact Information

Andrew Zenger
Global Product Manager
[email protected]
(716) 715-7417

SOURCE: ZeptoMetrix



View the original press release on ACCESS Newswire

Media

More from this category

  • Biotechnology
  • 06/06/2026
  • 08:05
AusBiotech

Opposition to proposed R&D Tax Incentive change unites Australia’s biotech, medtech and health tech sector

6 June 2026 Proposed Budget changes to the Research and Development Tax Incentive (RDTI) will disproportionally impact Australia’s biotech, medtech and health tech sector forcing more home-grown companies to consider moving overseas. Nine leading health and life sciences organisations: AusBiotech, Pathology Technology Australia, MTPConnect, ANDHealth, Life Sciences Queensland, Life Sciences WA, BioNSW, BioMelbourne Network and ARCS Australia, have co-signed a letter to Treasurer Jim Chalmers asking for an urgent review of RDTI changes proposed in the Federal Budget. While the sector shares concerns regarding a number of tax changes including to CGT, a proposal to limit the RDTI’s long standing…

  • Biotechnology
  • 04/06/2026
  • 06:17
Iovance Biotherapeutics, Inc.

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Therapeutic Goods Administration (TGA) of Australia granted approval with conditions of Amtagvi® (lifileucel), a tumor-derived autologous T cell immunotherapy, for previously treated advanced (metastatic or unresectable) melanoma. Amtagvi is indicated for the treatment of adult patients with…

  • Biotechnology, Medical Health Aged Care
  • 29/05/2026
  • 08:44
Denteric

Denteric Commences a Phase I Safety Study in Patients with Early Alzheimer’s Disease

Melbourne, Australia — Denteric today announced the commencement of participant recruitment for a Phase I clinical study of its first-in-class therapy for Alzheimer’s disease. Alzheimer’s disease remains one of the greatest medical challenges of our time and with an aging population this will only increase. Approximately 38 million people globally and 7 million in the US alone live with Alzheimer’s disease. A growing body of research links the progression of Alzheimer’s disease with exposure to chronic bacterial and viral infections. Porphyromonas gingivalis, a bacterium that commonly infects tooth pockets and causes chronic inflammation, has been shown to release toxic proteins…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.